As the crypto market faces turbulence, stablecoin giant Tether is leveraging its massive profits and gold reserves to fund a sweeping vision for peer-to-peer technologies, aiming to reshape everything from communications to agriculture.
As Bob Iger prepares for his second departure, the Disney CEO outlines a forward-looking mandate for his successor during an earnings call, emphasizing evolution in a dynamic media landscape.
Stephens lowers price target on Cal-Maine Foods (CALM) citing near-term oversupply pressures, but the egg producer's long-term strategy remains focused on expanding its cage-free capacity through acquisition.
A relentless focus on dividend yield may have led retirees and income investors to overlook one of the market's top performers. The Invesco NASDAQ 100 ETF (QQQM), with its scant 0.51% yield, has delivered over 108% total returns since inception by betting on growth, not income—a stark lesson in opportunity cost.
With the FIFA World Cup in North America, the Milano Cortina Winter Olympics, and a packed calendar of major events, 2026 is poised to be a landmark year for sports. Brands and retailers are deploying sophisticated strategies that prioritize cultural marketing and community engagement over mere sales spikes, navigating a landscape where consumer loyalty is won through storytelling, not just sponsorship.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
As Bob Iger prepares to step down, he highlights a 'healthy competition' between Disney's resurgent parks and its entertainment division to become the company's primary profit driver, with the board close to naming his successor.
Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Seven Wisconsin employers filed WARN notices in January, yet the state's unemployment rate held steady at a low 3.1%. Economists point to a cooling but stable labor market, with significant workforce changes driven by retirements and sectoral shifts.
NETSTREIT Corp. (NYSE: NTST) has delivered impressive shareholder returns over the past year, significantly outpacing its longer-term performance. As the stock hovers near $19, investors and analysts are debating whether its current price fully reflects the fundamentals of this necessity-based retail REIT or if momentum has gotten ahead of value.
Shares of the packaged food giant have slumped over the past year, raising questions about whether the stock is a bargain or a value trap. A deep dive into valuation metrics suggests significant upside potential.
A catastrophic landslide has torn through the historic Sicilian town of Niscemi, forcing mass evacuations and exposing a legacy of bureaucratic delays and unheeded geological warnings that left the community perilously vulnerable.
A newly surfaced 2014 email from the Jeffrey Epstein documents reveals Bitcoin-aligned executives warning investors about backing rival projects like Ripple. Some XRP proponents are framing the disclosure as validation of the token's early significance, though market momentum remains bearish.
With a partial government shutdown entering its third day, the House prepares to vote on a Senate-crafted funding deal. While Speaker Johnson eyes a Tuesday resolution, deep partisan divisions over Homeland Security funding and procedural hurdles threaten to prolong the stalemate, leaving thousands of federal employees working without pay.
Facing stiff competition from synthetic fibers, the cotton industry's leading research and promotion body has created a chief marketing officer role and merged its marketing teams to drive demand across the entire supply chain.
